Comparing the current results to its competitors, Kiromic Biopharma Inc reported Revenue decrease in the 4 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 241.3 %, recorded in the same quarter.
Kiromic Biopharma Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment within the solid tumor therapies market, facing competition from biopharmaceutical companies, academic research institutions, governmental agencies, and both public and private research institutions, as well as established standard of care treatments. Competition is increasing from companies developing allogeneic T cell therapies, including those based on alpha/beta and gamma/delta T cells. Competitors in the alpha/beta T cell platform include Fate Therapeutics, Poseida Therapeutics, and Allogene Therapeutics. In the gamma/delta T cell platform space, competitors include Adicet Bio, Inc., Cytomed Therapeutics, IN8 Bio, Inc., TC Biopharm Limited, and GammaDelta Therapeutics Limited, which was acquired by Takeda. Additional competition comes from companies developing non-cell-based immune therapies and other treatments, such as Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Incyte Corporation, Merck & Co., Inc., F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., Xencor Inc., MacroGenics, Inc., GlaxoSmithKline plc, and Seattle Genetics, Inc. These companies are pursuing bispecific antibodies and antibody-drug conjugates targeting cancer cells. Many competitors possess greater financial resources and capabilities in research, development, manufacturing, and marketing, which may affect the company's commercial prospects.
September 19, 2024
CSIMarket.com Kiromic BioPharma, Inc. recently received a unanimous recommendation from their Safety Monitoring Committee (SMC) to progress the Deltacel-01 clinical trial to its expansion phase. The study focuses on the therapeutic efficacy and safety of Deltacel (KB-GDT-01), an allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have shown resistance to conventional treatments. This landmark decision propels Kiromic’s efforts to establish a novel treatment paradigm for this high-burden disease.Non-small cell lung cancer (NSCLC) is a prevalent and challenging malignancy, particularly in its advanced stages. For patients ...
August 11, 2024
HOUSTON - Kiromic BioPharma, Inc. (OTCQB: KRBP) (Kiromic or the Company) Provides Update on Part 1 of the Deltacel-01 Trial Kiromic BioPharma, Inc., a leading biotechnology company, has announced promising interim results from Part 1 of its ongoing Deltacel-01 Phase 1 clinical trial. The trial is aimed at evaluating the efficacy and safety of Deltacel (KB-GDT-01), an allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have not responded to standard treatments.The Deltacel-01 trial represents a pioneering approach in the use of GDT therapy, which leverages the natural immunological properties of gamma delta T-cells to combat ca...
August 10, 2024
Kiromic BioPharma Reports Promising Interim Results in Phase 1 Deltacel-01 Trial for Advanced NSCLC Patients Houston-based biotech firm Kiromic BioPharma, Inc. (OTCQB: KRBP) has released interim results that are near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial is a critical step in evaluating the efficacy and safety of Deltacel (KB-GDT-01), Kiromic’s innovative allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy. Targeted at patients suffering from stage 4 metastatic non-small cell lung cancer (NSCLC) who have not responded to standard treatments, the trial is generating much anticipation within the medical community. About the TrialThe Deltacel-01 Phase 1 trial i...
August 9, 2024
Kiromic BioPharma (OTCQB: KRBP) has reported a series of promising developments from its Deltacel-01 Phase 1 clinical trial, which is focused on evaluating Deltacel (KB-GDT-01), the Company s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy. This trial targets patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have failed to respond to standard therapies. Interim Results from Part 1 of the Deltacel-01 Trial According to the most recent updates, Kiromic BioPharma has released interim results that nearly conclude Part 1 of the Deltacel-01 trial. This part of the trial has evaluated the efficacy and safety of Deltacel in five patients with advanced NSCLC. While specific quantita...
August 1, 2024
Houston, TX Kiromic BioPharma, Inc. (OTCQB: KRBP) an emerging leader in the field of immuno-oncology recently announced encouraging results from the ongoing Deltacel-01 Phase 1 clinical trial. The trial is focused on evaluating the safety and efficacy of Deltacel (KB-GDT-01), an allogeneic, off-the-shelf Gamma Delta T-cell (GDT) therapy, in patients suffering from stage 4 metastatic non-small cell lung cancer (NSCLC) who have become refractory to standard treatments. The early data are inspiring hope among both researchers and patients.The data reveal that, eight months following treatment, the first patient enrolled in the Deltacel-01 trial achieved a notable 20% reduction in tumor size. These result...
July 18, 2024
Kiromic BioPharma Advances Deltacel-01 Clinical Trial to Expansion PhaseHouston-based biopharmaceutical company, Kiromic BioPharma, Inc., has announced its plans to advance the Deltacel-01 Phase 1 clinical trial to the Expansion Phase. This decision comes as a result of a positive assessment from the Deltacel-01 Safety Monitoring Committee (SMC), which reviewed safety and efficacy data collected thus far and confirmed favorable results and optimal dosage.The Deltacel-01 trial focuses on evaluating Deltacel (KB-GDT-01), Kiromic s allogeneic and off-the-shelf Gamma Delta T-cell (GDT) therapy. The therapy is being tested in patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have not respon...
June 6, 2024
Kiromic BioPharma, a leading biotechnology company, has recently announced encouraging six-month follow-up results from the first patient enrolled in their groundbreaking Deltacel-01 Phase 1 clinical trial. This trial aims to evaluate the efficacy of Deltacel (KB-GDT-01), an allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with advanced-stage 4 metastatic non-small cell lung cancer (NSCLC) who have not responded to standard treatments.Lung cancer remains one of the most common and deadly cancers worldwide, particularly when it reaches the advanced stage. Conventional treatments often fail to achieve significant results, leaving patients with limited options and poor prognosis. Kiromic...
Avalon Globocare Corp's business model is focused on providing innovative healthcare solutions and services through strategic acquisitions, partnerships, and collaborations in the biotechnology and healthcare sectors.
Gamida Cell Ltd's business model is focused on developing and bringing innovative cell therapies to market for the treatment of various diseases, with a particular emphasis on hematological malignancies and serious blood disorders.
Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.
Intensity Therapeutics Inc's business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.
Sources:
Kiromic Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kiromic Biopharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
